TABLE 1.
Antimicrobial susceptibility profiles of the E. anophelis C08 strain
| Antibiotics | Breakpoint (µg/mL)a |
EM361-97b |
C08 |
||||
|---|---|---|---|---|---|---|---|
| S | I | R | MIC (µg/mL) | Result | MIC (µg/mL) | Result | |
| Ticarcillin-clavulanate | ≤16/2 | 32/2–64/2 | ≥128/2 | >64/2 | I | >128 | R |
| Piperacillin-tazobactam | ≤16/4 | 32/4–64/4 | ≥128/4 | 16/4 | S | ≥128 | R |
| Cefotaxime | ≤8 | 16–32 | ≥64 | ND | ND | 32 | I |
| Ceftazidime | ≤8 | 16 | ≥32 | >16 | I | >32 | R |
| Cefepime | ≤8 | 16 | ≥32 | 32 | R | >32 | R |
| Ciprofloxacin | ≤1 | 2 | ≥4 | >2 | I | >4 | R |
| Tetracycline | ≤4 | 8 | ≥16 | >8 | I | 128 | R |
| Doxycycline | ≤4 | 8 | ≥16 | ND | ND | 4 | S |
| Minocycline | ≤4 | 8 | ≥16 | <1 | S | 2 | S |
| Tigecycline | ≤2 | 4 | ≥8 | 2 | S | 8 | R |
| Colistin | ≤2 | ≥4 | ND | ND | >4 | R | |
| Polymyxin B | ≤2 | ≥4 | ND | ND | >4 | R | |
| Gentamicin | ≤4 | 8 | ≥16 | >8 | R | >8 | R |
| Amikacin | ≤16 | 32 | ≥64 | >32 | R | >32 | R |
| Levofloxacin | ≤2 | 4 | ≥8 | >8 | R | 2 | S |
| Aztreonam | ≤8 | 16 | ≥32 | >16 | I | >16 | R |
| Imipenem | ≤4 | 8 | ≥16 | >8 | I | >8 | R |
| Meropenem | ≤4 | 8 | ≥16 | >8 | I | >8 | R |
| Trimethoprim-Sulfamethoxazole | ≤2/38 | 32/2–64/2 | ≥4/76 | >4/76 | R | 4 | R |
| Chloramphenicol | ≤8 | 16 | ≥32 | ND | ND | ≥64 | R |
a
MIC breakpoints (micrograms per milliliter) applied to isolates according to Clinical and Laboratory Standards Institute (CLSI) “other non-Enterobacteriaceae” organisms (there are no interpretive criteria for the susceptibility of E. anophelis).
b
The MICs of E. anophelis EM361-97 were obtained from a previous study by Lin et al. (49). ND, not determined.